Kala Biopharmaceuticals Submits Form 144 Filing – What You Need to Know
In a recent SEC filing, KALA Pharmaceuticals, Inc. (Ticker: KALA, CIK: 0001479419) submitted a Form 144 indicating the intention to sell restricted shares. This filing is significant as it provides insight into potential market activity by the company’s insiders or major shareholders. Form 144 is typically filed by individuals or entities looking to sell restricted stock, and while it does not mean an immediate sale, it signals an intent to do so in the near future.
KALA Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for eye diseases. Their innovative products aim to address unmet needs in ophthalmology and improve the lives of patients. For more information about KALA Pharmaceuticals, Inc., you can visit their official website at https://www.kalarx.com/.
Form 144 is a notice of proposed sale of securities filed with the Securities and Exchange Commission. It is required when an individual or entity plans to sell restricted shares or securities in the open market. This filing provides transparency to investors and helps prevent insider trading.
Read More:
Kala Biopharmaceuticals Submits Form 144 SEC Filing (0001479419) – What You Need to Know
